BACKGROUND: @entity320 is an aggressive @entity5 with an increasing incidence. Exosomes are actively secreted microvesicles, whose characteristics reflect those of the cell they are originated in. The aim of this study was to identify and evaluate the presence of the @entity320 biomarkers MIA, @entity4483 and @entity22920 ( @entity22920 ) in exosomes and their potential clinical utility. METHODS: Serum samples were obtained from stage IV @entity320 @entity1 , @entity320 -free @entity1 and healthy controls. Exosomes were precipitated and @entity22920 , MIA and @entity4483 concentrations were quantified in serum, exosomes, and exosome-free serum. RESULTS: Both MIA and @entity4483 were detected in exosomes and correlated significantly with serum concentrations ( @entity4483 : r=0.968; MIA: r=0.799; p<0.001). MIA and @entity4483 concentrations in exosomes were significantly higher in @entity320 @entity1 than in healthy controls and disease-free @entity1 . However, @entity22920 concentrations in exosomes did not differ between these three groups. ROC curves analysis rendered AUCs for MIA of 0.883 (p<0.01) and of 0.840 for @entity4483 (p<0.01). @entity1 with exosome MIA concentration higher than 2.5 g/L showed shorter median survival related to those with lower level (4 versus 11months; p<0.05). CONCLUSIONS: MIA and @entity4483 can be detected in exosomes from @entity320 @entity1 and their quantification presents diagnostic and prognostic utility.

Circulating XXXX exosomes as diagnostic and prognosis biomarkers.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity4483 :: ('6285', 'Gene') :: ['S100B'] @entity22920 :: ('1638', 'Gene') :: ['TYRP2', 'tyrosinase-related protein 2'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'Malignant melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['melanoma']
